Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19
May 10, 2024 02:00 ET
|
Sanofi - Aventis Groupe
Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19 L’accord, qui combinera la...
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
May 10, 2024 02:00 ET
|
Sanofi - Aventis Groupe
Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader...
Alcoholic Hepatitis Treatment Market To Reach USD 4.9 Billion By 2032 | DataHorizzon Research
May 09, 2024 14:10 ET
|
DataHorizzon Research
Fort Collins, Colorado, May 09, 2024 (GLOBE NEWSWIRE) -- The growing prevalence of alcohol-related liver diseases drives the demand for alcoholic hepatitis treatment in the forecast period. The...
Psoriasis Vulgaris Clinical Trial Pipeline Analysis Demonstrates 50+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
May 09, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 09, 2024 (GLOBE NEWSWIRE) -- Psoriasis Vulgaris Clinical Trial Pipeline Analysis Demonstrates 50+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm,...
Hyaluronic Acid Market Surges to USD 18.75 Billion by 2031, Propelled by 8.7% CAGR - Verified Market Research®
May 09, 2024 10:15 ET
|
Verified Market Research
Lewes, Delaware, May 09, 2024 (GLOBE NEWSWIRE) -- The Global Hyaluronic Acid Market is projected to grow at a CAGR of 8.7% from 2024 to 2031, according to a new report published by Verified Market...
ACELYRIN, INC. Announces Leadership Transition
May 09, 2024 08:00 ET
|
ACELYRIN, INC.
Mina Kim appointed Chief Executive Officer and to Board of Directors ACELYRIN Founder Shao-Lee Lin, M.D., Ph.D., steps down as Chief Executive Officer Shephard (Shep) Mpofu, M.D., MRCP, FRCP...
Royalty Pharma Reports First Quarter 2024 Results
May 09, 2024 07:00 ET
|
Royalty Pharma plc
Royalty Receipts growth of 14% driving Portfolio Receipts of $717 millionNet cash provided by operating activities of $665 millionFull year 2024 guidance confirmed: Portfolio Receipts expected to be...
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
May 09, 2024 06:45 ET
|
Royalty Pharma plc
Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands Royalty Pharma’s development-stage portfolio to...
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 08, 2024 16:10 ET
|
IGM Biosciences, Inc.
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW,...
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
May 08, 2024 16:02 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...